186 related articles for article (PubMed ID: 11709365)
1. Mechanism of action of the des-F(6) quinolone BMS-284756 measured by supercoiling inhibition and cleavable complex assays.
Wu P; Lawrence LE; Denbleyker KL; Barrett JF
Antimicrob Agents Chemother; 2001 Dec; 45(12):3660-2. PubMed ID: 11709365
[TBL] [Abstract][Full Text] [Related]
2. The inhibition and selectivity of bacterial topoisomerases by BMS-284756 and its analogues.
Lawrence LE; Wu P; Fan L; Gouveia KE; Card A; Casperson M; Denbleyker K; Barrett JF
J Antimicrob Chemother; 2001 Aug; 48(2):195-201. PubMed ID: 11481288
[TBL] [Abstract][Full Text] [Related]
3. Unique biological properties and molecular mechanism of 5,6-bridged quinolones.
Macinga DR; Renick PJ; Makin KM; Ellis DH; Kreiner AA; Li M; Rupnik KJ; Kincaid EM; Wallace CD; Ledoussal B; Morris TW
Antimicrob Agents Chemother; 2003 Aug; 47(8):2526-37. PubMed ID: 12878515
[TBL] [Abstract][Full Text] [Related]
4. The in vitro activity of BMS-284756, a new des-fluorinated quinolone.
Weller TM; Andrews JM; Jevons G; Wise R
J Antimicrob Chemother; 2002 Jan; 49(1):177-84. PubMed ID: 11751785
[TBL] [Abstract][Full Text] [Related]
5. Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance.
Low DE; Muller M; Duncan CL; Willey BM; de Azavedo JC; McGeer A; Kreiswirth BN; Pong-Porter S; Bast DJ
Antimicrob Agents Chemother; 2002 Apr; 46(4):1119-21. PubMed ID: 11897603
[TBL] [Abstract][Full Text] [Related]
6. The inhibition of supercoiling activity of DNA gyrase from Micrococcus luteus caused by rufloxacin (MF 934) and MF 961.
Fabbri S; Broggini M; Pagella P; D'Incalci M
J Antimicrob Chemother; 1991 May; 27(5):687-9. PubMed ID: 1653205
[No Abstract] [Full Text] [Related]
7. Mechanism of inhibition of DNA gyrase by ES-1273, a novel DNA gyrase inhibitor.
Oyamada Y; Yamagishi J; Kihara T; Yoshida H; Wachi M; Ito H
Microbiol Immunol; 2007; 51(10):977-84. PubMed ID: 17951987
[TBL] [Abstract][Full Text] [Related]
8. A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase.
Hilliard JJ; Krause HM; Bernstein JI; Fernandez JA; Nguyen V; Ohemeng KA; Barrett JF
Adv Exp Med Biol; 1995; 390():59-69. PubMed ID: 8718602
[TBL] [Abstract][Full Text] [Related]
9. A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II.
Gruger T; Nitiss JL; Maxwell A; Zechiedrich EL; Heisig P; Seeber S; Pommier Y; Strumberg D
Antimicrob Agents Chemother; 2004 Dec; 48(12):4495-504. PubMed ID: 15561817
[TBL] [Abstract][Full Text] [Related]
10. Inhibition by quinolones of DNA gyrase from Staphylococcus aureus.
Tanaka M; Sato K; Kimura Y; Hayakawa I; Osada Y; Nishino T
Antimicrob Agents Chemother; 1991 Jul; 35(7):1489-91. PubMed ID: 1656864
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of differential activities of ofloxacin enantiomers.
Morrissey I; Hoshino K; Sato K; Yoshida A; Hayakawa I; Bures MG; Shen LL
Antimicrob Agents Chemother; 1996 Aug; 40(8):1775-84. PubMed ID: 8843280
[TBL] [Abstract][Full Text] [Related]
12. Clerocidin, a terpenoid antibiotic, inhibits bacterial DNA gyrase.
McCullough JE; Muller MT; Howells AJ; Maxwell A; O'Sullivan J; Summerill RS; Parker WL; Wells JS; Bonner DP; Fernandes PB
J Antibiot (Tokyo); 1993 Mar; 46(3):526-30. PubMed ID: 8386713
[No Abstract] [Full Text] [Related]
13. Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756.
Hartman-Neumann S; DenBleyker K; Pelosi LA; Lawrence LE; Barrett JF; Dougherty TJ
Antimicrob Agents Chemother; 2001 Oct; 45(10):2865-70. PubMed ID: 11557482
[TBL] [Abstract][Full Text] [Related]
14. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage.
Chen CR; Malik M; Snyder M; Drlica K
J Mol Biol; 1996 May; 258(4):627-37. PubMed ID: 8636997
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of quinolones against Escherichia coli DNA gyrase.
Yoshida H; Nakamura M; Bogaki M; Ito H; Kojima T; Hattori H; Nakamura S
Antimicrob Agents Chemother; 1993 Apr; 37(4):839-45. PubMed ID: 8388200
[TBL] [Abstract][Full Text] [Related]
16. In vitro cleavable-complex assay to monitor antimicrobial potency of quinolones.
Walton L; Elwell LP
Antimicrob Agents Chemother; 1988 Jul; 32(7):1086-9. PubMed ID: 2847641
[TBL] [Abstract][Full Text] [Related]
17. 6-hydroxy derivative as new desfluoroquinolone (DFQ): synthesis and DNA-binding study.
Tabarrini O; Sissi C; Fravolini A; Palumbo M
Nucleosides Nucleotides Nucleic Acids; 2000 Aug; 19(8):1327-36. PubMed ID: 11097062
[TBL] [Abstract][Full Text] [Related]
18. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
Strahilevitz J; Robicsek A; Hooper DC
Antimicrob Agents Chemother; 2006 Feb; 50(2):600-6. PubMed ID: 16436716
[TBL] [Abstract][Full Text] [Related]
19. [In vitro and in vivo antibacterial activities of a new quinolone derivative, FD501].
Imamori K; Asaoka T; Matsumoto M; Maebashi K; Matsuda H; Tahara Y
Jpn J Antibiot; 1996 Mar; 49(3):264-72. PubMed ID: 8935122
[TBL] [Abstract][Full Text] [Related]
20. Advances in DNA gyrase inhibitors.
Kim OK; Ohemeng K; Barrett JF
Expert Opin Investig Drugs; 2001 Feb; 10(2):199-212. PubMed ID: 11178337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
